LNDC Landec Corp.

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.

Details regarding Lifecore’s participation are as follows:

  • 43rd Annual J.P. Morgan Healthcare Conference

    Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings

    Conference Dates: January 13-16, 2025

    Location: San Francisco, California

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at .



Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
 

Tim Brons (Media)
415-675-7402
 

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
 
EN
06/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical Further Strengthens Financial Position Through Sal...

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has entered into a sales agreement with a non-competitive buyer for the company’s previously purchased, but not yet instal...

 PRESS RELEASE

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthca...

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 43rd Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includin...

 PRESS RELEASE

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Resul...

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million, and Favorable Restructuring of Credit Facility with BMO -- Conference Call Today at 4:30pm ET CHASKA, Minn., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), tod...

 PRESS RELEASE

Lifecore Biomedical to Report Financial Results for Second Quarter of ...

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025 Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter of fiscal year 2025 on Thursday, January 2, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast ...

 PRESS RELEASE

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services S...

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum’s NIH-Funded NRS-033 Development Program CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organizati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch